Search - tctmd.com

Displaying 41 - 60 of 144

Sort: Relevancy | Date

Presentation THT 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Presenter: Arvind Kumar Venkataramana Raju

February 11, 2025

Presentation THT 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

Presentation TCT 2024

TCT 813: Long-Term Outcomes of Dapagliflozin in Acute Myocardial Infarction and Preserved Ejection Fraction

Presenter: Bu-Yuan Hsiao

October 29, 2024

Presentation TCT 2024

TCT 132: Impact of Comorbid Heart Failure With Reduced Ejection Fraction (HFrEF) in the Development of Arrhythmias Among Patients Hospitalized for Transcatheter Aortic Valve Replacement (TAVR)

Presenter: Bruce Adrian Casipit

October 29, 2024

Presentation TCT 2024

TCT 468: No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly-Reduced Ejection Fraction: Twelve-Month Outcomes From Multi-Center Pilot Feasibility Studies

Presenter: Brian Potter

October 28, 2024

Presentation NY Valves 2024

The Effect of Baseline Left Ventricular Ejection Fraction on Reverse Remodeling After Jenavalve Trilogy Transcatheter Aortic Valve Replacement in Patients With Pure Aortic Regurgitation: An Analysis From the ALIGN-AR Trial

Presenter: Lauren Sharan Ranard

June 07, 2024

Presentation NY Valves 2024

Aortic Valve Replacement Versus Clinical Surveillance in Moderate Aortic Stenosis With Reduced Ejection Fraction: Meta-Analysis of Reconstructed Time-to-Event Data

Presenter: Omar M. Abdelfattah

June 07, 2024

Presentation NY Valves 2024

Impact of Baseline Left Ventricular Ejection Fraction on Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: Insights From the WIN-TAVI Registry

Presenter: Francesca Maria Di Muro

June 06, 2024

Presentation NY Valves 2024

Predictors and Clinical Impact of Worsening Left Ventricular Ejection Fraction After Mitral Transcatheter Edge-to-Edge Repair

Presenter: Sachiyo Ono

June 05, 2024

Presentation NY Valves 2024

Prophylactic VA-ECMO for TAVI Using Self-Expandable Valves in Patients With Cardiogenic Shock and a Left Ventricular Ejection Fraction Below 30%

Presenter: Eduardo A. Arias

June 05, 2024

Presentation THT 2024

The Role of AF Ablation in HF Across the Spectrum of Ejection Fractions

Presenter: Kevin Makati

March 05, 2024

Presentation THT Abstracts 2024

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Presenter: Alexandra Steverson

March 05, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Presenter: Sanjiv J. Shah

March 05, 2024

Presentation THT Abstracts 2024

Effect of Expert Team Consultation for Adjustment of Guideline Directed Medical Therapy on Heart Failure Related Adverse Outcomes in Patients with Reduced Ejection Fraction

Presenter: Joseph Maenza

March 04, 2024

Presentation THT Abstracts 2024

Interim Results from Adaptive Randomized Controlled Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure due to Reduced Left Ventricular Ejection Fraction (HFrEF)

Presenter: Amish Raval

March 04, 2024

Advertisement

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

TCT 813: Long-Term Outcomes of Dapagliflozin in Acute Myocardial Infarction and Preserved Ejection Fraction

TCT 132: Impact of Comorbid Heart Failure With Reduced Ejection Fraction (HFrEF) in the Development of Arrhythmias Among Patients Hospitalized for Transcatheter Aortic Valve Replacement (TAVR)

TCT 468: No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly-Reduced Ejection Fraction: Twelve-Month Outcomes From Multi-Center Pilot Feasibility Studies

The Effect of Baseline Left Ventricular Ejection Fraction on Reverse Remodeling After Jenavalve Trilogy Transcatheter Aortic Valve Replacement in Patients With Pure Aortic Regurgitation: An Analysis From the ALIGN-AR Trial

Aortic Valve Replacement Versus Clinical Surveillance in Moderate Aortic Stenosis With Reduced Ejection Fraction: Meta-Analysis of Reconstructed Time-to-Event Data

Impact of Baseline Left Ventricular Ejection Fraction on Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: Insights From the WIN-TAVI Registry

Predictors and Clinical Impact of Worsening Left Ventricular Ejection Fraction After Mitral Transcatheter Edge-to-Edge Repair

Prophylactic VA-ECMO for TAVI Using Self-Expandable Valves in Patients With Cardiogenic Shock and a Left Ventricular Ejection Fraction Below 30%

The Role of AF Ablation in HF Across the Spectrum of Ejection Fractions

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Effect of Expert Team Consultation for Adjustment of Guideline Directed Medical Therapy on Heart Failure Related Adverse Outcomes in Patients with Reduced Ejection Fraction

Interim Results from Adaptive Randomized Controlled Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure due to Reduced Left Ventricular Ejection Fraction (HFrEF)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content